- Home
- FRA vs LAB Comparison
FRA vs LAB Comparison
Compare FRA & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRA | LAB |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.1M | 480.7M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | FRA | LAB |
|---|---|---|
| Price | $11.79 | $1.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 165.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 11.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $169,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 79.77 |
| 52 Week Low | $11.33 | $0.92 |
| 52 Week High | $13.10 | $2.14 |
Technical Indicators
Market Signals| Indicator | FRA | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 39.35 |
| Support Level | $11.62 | $1.46 |
| Resistance Level | $11.83 | $1.72 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 74.19 | 10.20 |
Price Performance
Historical ComparisonAbout FRA Blackrock Floating Rate Income Strategies Fund Inc
Blackrock Floating Rate Inc Stra Fd Inc is a United States-based diversified closed-ended management investment company. The Fund's investment objective is to provide shareholders with high current income and preservation of capital with investment in a diversified, leveraged portfolio consisting of floating-rate debt securities and instruments.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.